The effects of topical ketorolac and indomethacin on measles conjunctivitis: randomized controlled trial.
OBJECTIVE
To compare the effect of topical ketorolac and indomethacin on measles conjunctivitis.


METHODS
Prospective double-masked placebo-controlled randomized trial.


METHODS
Sixty-two patients with severe measles conjunctivitis were included in this study. All patients were hospitalized and randomly assigned to receive ketorolac 0.5% or indomethacin 0.1% in the right eye and artificial tears in the left eye. Conjunctival hyperemia, burning sensations, foreign-body sensations, and photophobia scores were conducted at baseline and at days seven and 14. A satisfaction score was evaluated at the end of the study.


RESULTS
The conjunctival injection score of the control eyes was significantly higher than those of the ketorolac- and indomethacin-treated eyes at day seven (P < .05). The conjunctival injection score of the ketorolac-treated eyes was lower than that of the indomethacin-treated eyes at days seven and 14, but this did not reach statistical significance. There was no significant difference in the burning and foreign-body sensations and in the photophobia scores among the study eyes at baseline, day seven, and day 14 (P > .05). There was no significant difference in the satisfaction score among the study eyes at the end of the study (P > .05).


CONCLUSIONS
In patients with measles during the first two weeks of infection, ketorolac and indomethacin were more effective than artificial tears in decreasing conjunctival hyperemia, but burning sensations, foreign-body sensations, and photophobia were unaffected.
Toker
Mustafa Ilker
MI
Department of Ophthalmology, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey. ilkertoker@cumhuriyet.edu.tr
Erdem
Hakan
H
Erdogan
Haydar
H
Arici
Mustafa Kemal
MK
Topalkara
Aysen
A
Arslan
Osman Sevki
OS
Pahsa
Alaaddin
A
D000287:Administration, Topical; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003228:Conjunctiva / Q000098:blood supply; D003236:Conjunctivitis, Viral / Q000188:drug therapy* / Q000453:epidemiology; D004311:Double-Blind Method; D006801:Humans; D006940:Hyperemia / Q000188:drug therapy; D007213:Indomethacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020911:Ketorolac Tromethamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008457:Measles / Q000188:drug therapy* / Q000453:epidemiology; D008459:Measles virus / Q000187:drug effects*; D008889:Military Personnel; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017060:Patient Satisfaction; D020795:Photophobia / Q000188:drug therapy; D011446:Prospective Studies; D014421:Turkey / Q000453:epidemiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D009883:Ophthalmic Solutions; D020911:Ketorolac Tromethamine; D007213:Indomethacin